Press Releases

SOUTH PLAINFIELD, N.J. , Nov. 19,  2015 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that it has completed enrollment of ACT CF, the company's second Phase 3 clinical trial of Translarna™ (ataluren) for patients with nonsense mutation cystic fibrosis (nmCF).

- 152 DMD patients now on Translarna™ (ataluren) commercial therapy -
- Strong sales growth with YTD 9/30 Translarna revenues of $21.0M -
- Phase 3 ACT DMD clinical trial results confirm clinical benefit of Translarna -
- SMA program expected to resume clinical development in early 2016 -

SOUTH PLAINFIELD, N.J. , Nov. 3, 2015 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced  that management will present a company update at the following conferences: Credit Suisse 24 th Annual Healthcare Conference, on Wednesday, November 11 th at 8:30 a.m.

Program Recognizes Excellence and Innovation of Nonprofit Organizations Serving the Cystic Fibrosis Patient Community

SOUTH PLAINFIELD, N.J. , Oct. 27, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2015 financial results and provide an update on the Company's business, outlook and clinical programs.

- PTC plans to complete rolling NDA submission to the FDA by end of 2015 -
- Totality of clinical data demonstrate Translarna's ability to slow disease progression for patients with nonsense mutation Duchenne muscular dystrophy -
- 15 meter benefit observed in 6MWD in overall study population (p=0.213, n=228) -
- 47 meter benefit observed in 6MWD in pre-specified subgroup of 300 - 400 meters at baseline (p=0.007, n=99) -
- Pre-specified meta-analysis of combined ACT DMD and Phase 2b studies demonstrated benefit in Translarna-treated patients across primary (p=0.015, n=291) and key secondary efficacy endpoints -
- Strong safety profile of Translarna confirmed, consistent with previous studies -
--Conference call scheduled today at 5:00 PM ET--

- RG7800 demonstrated a favorable safety profile and was well tolerated over 12 weeks of treatment in patients with SMA -
- Up to two-fold increases in SMN protein versus baseline were observed in patients receiving treatment with RG7800 -

SOUTH PLAINFIELD, N.J. , Oct. 2, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on October 2, 2015 it approved non-statutory stock options to purchase an aggregate of 58,300 shares of its common stock to 13 new employees.

- First potential disease-modifying treatment for people with nonsense mutation cystic fibrosis, the most severe form of the disease -

STRIVE Awards Program Recognizes Excellence and Innovation in the Global Duchenne Muscular Dystrophy Community